Cervical cancer immunotherapy chemoradiotherapy FDA approval with checkpoint inhibitor curative treatment
RegulatoryBusiness Wire

Merck Receives FDA Approval for Keytruda Plus Chemoradiotherapy in Cervical Cancer

Merck announces FDA approval of pembrolizumab plus chemoradiotherapy for adults with high-risk locally advanced cervical cancer.

Merck today announced that the FDA has approved KEYTRUDA (pembrolizumab) plus concurrent chemoradiotherapy followed by KEYTRUDA maintenance for the treatment of adults with FIGO 2014 Stage III-IVA cervical cancer. In the Phase 3 KEYNOTE-A18 trial, KEYTRUDA plus chemoradiotherapy demonstrated a statistically significant improvement in progression-free survival. This approval establishes KEYTRUDA plus chemoradiotherapy as a new standard of care in the curative-intent treatment of locally advanced cervical cancer.

Original Source

Business Wire
Share:

Previous

Pfizer Announces Updated Paxlovid Label Including New Patient Populations

Next

AstraZeneca Receives FDA Approval for Tezspire in Pediatric Severe Asthma